Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age

BACKGROUND: Pneumococcal conjugate vaccines (PCVs) have significantly decreased pneumococcal disease worldwide; however, expanding serotype coverage may further reduce disease burden. A 20-valent PCV (PCV20) containing capsular polysaccharide conjugates of serotypes present in the 13-valent PCV (PCV...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurley, Donald, Griffin, Carl, Young, Mariano, Scott, Daniel A, Pride, Michael W, Scully, Ingrid L, Ginis, John, Severs, Joseph, Jansen, Kathrin U, Gruber, William C, Watson, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492133/
https://www.ncbi.nlm.nih.gov/pubmed/32716500
http://dx.doi.org/10.1093/cid/ciaa1045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492133/
https://www.ncbi.nlm.nih.gov/pubmed/32716500
http://dx.doi.org/10.1093/cid/ciaa1045

Ejemplares similares